| Expression System | CHO |
| Aggregation | < 5% as determined by SEC-HPLC |
| Purity | > 95% as determined by SDS-PAGE |
| Species Reactivity | Human |
| Clone | bimekizumab |
| Source/Isotype | Human IgG1,Kappa |
| Application | / |
| Specificity | Detects IL17A、IL17F |
| Gene | IL17A&IL17F |
| Other Names | IL17A: IL-17A,Interleukin-17A,CTLA-8,IL-17 IL17F: CANDF6, IL-17F, ML-1, ML1 |
| Background | IL17A and IL17F are central targets in the interleukin-17 family that synergistically drive autoimmune inflammation. The IL17A gene is located in the p12.1 region of human chromosome 6 and encodes a proinflammatory cytokine of 155 amino acids, which induces the secretion of inflammatory mediators such as IL-6 and CXCL8 through the activation of the NF-κb/MAPK pathway, and enhances the secretion of IL-6 and CXCL8, it drives neutrophil infiltration with epidermal proliferation in diseases such as rheumatoid arthritis and psoriasis; the IL17F gene is localized at 6p12.2, encoding a 163-amino acid homo/heterodimeric ligand, and the IL17F gene has been implicated in the pathogenesis of rheumatoid arthritis and psoriasis, after binding to the IL-17RA/RC receptor complex, it regulates antimicrobial peptide production and matrix remodeling by recruiting ACT1 adaptor proteins, which plays a key role in airway hyperresponsiveness in asthma and osteophyte formation in ankylosing spondylitis. They have 50% amino acid homology and can form three kinds of active dimers of IL-17A/A, IL-17A/F and IL-17F/F, which jointly mediate the chronic inflammatory cascade mediated by Th17 cells. |
| Formulation | Phosphate-buffered solution, pH 7.2-7.4. |
| Endotoxin | < 1 EU/mg, determined by LAL gel clotting assay |
| Expression System | CHO |
| Aggregation | < 5% as determined by SEC-HPLC |
| Purity | > 95% as determined by SDS-PAGE |
| Species Reactivity | Human |
| Clone | bimekizumab |
| Source/Isotype | Human IgG1,Kappa |
| Application | / |
| Specificity | Detects IL17A、IL17F |
| Gene | IL17A&IL17F |
| Other Names | IL17A: IL-17A,Interleukin-17A,CTLA-8,IL-17 IL17F: CANDF6, IL-17F, ML-1, ML1 |
| Background | IL17A and IL17F are central targets in the interleukin-17 family that synergistically drive autoimmune inflammation. The IL17A gene is located in the p12.1 region of human chromosome 6 and encodes a proinflammatory cytokine of 155 amino acids, which induces the secretion of inflammatory mediators such as IL-6 and CXCL8 through the activation of the NF-κb/MAPK pathway, and enhances the secretion of IL-6 and CXCL8, it drives neutrophil infiltration with epidermal proliferation in diseases such as rheumatoid arthritis and psoriasis; the IL17F gene is localized at 6p12.2, encoding a 163-amino acid homo/heterodimeric ligand, and the IL17F gene has been implicated in the pathogenesis of rheumatoid arthritis and psoriasis, after binding to the IL-17RA/RC receptor complex, it regulates antimicrobial peptide production and matrix remodeling by recruiting ACT1 adaptor proteins, which plays a key role in airway hyperresponsiveness in asthma and osteophyte formation in ankylosing spondylitis. They have 50% amino acid homology and can form three kinds of active dimers of IL-17A/A, IL-17A/F and IL-17F/F, which jointly mediate the chronic inflammatory cascade mediated by Th17 cells. |
| Formulation | Phosphate-buffered solution, pH 7.2-7.4. |
| Endotoxin | < 1 EU/mg, determined by LAL gel clotting assay |
